Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate stabilization
Initial priorities
Resuscitation bay for K >= 6.5 mmol/L
Resuscitation bay for any hyperkalemia with ECG changes
Resuscitation bay for any hyperkalemia with hemodynamic instability
Cardiac monitor and defibrillation pads
Continuous ECG monitoring
Frequent blood pressure monitoring
IV access
Two large bore peripheral IV lines
Consider intraosseous access if IV delay
Point-of-care glucose
Baseline before insulin therapy
Repeat q 30 to 60 minutes after insulin
Early ECG
Repeat ECG after membrane stabilization
Repeat ECG for any rhythm change
Time-critical decision points
If malignant arrhythmia or cardiac arrest, hyperkalemia ACLS pathway
Immediate calcium
Immediate potassium shift therapies
If ECG changes present, do not delay treatment awaiting repeat potassium
Treat while confirming with repeat non-hemolyzed sample
Treat while evaluating for pseudohyperkalemia
If renal failure or refractory hyperkalemia, early nephrology
Dialysis planning during initial stabilization
Concurrent temporizing therapy while arranging dialysis
Hemodynamic and monitoring targets
Monitoring targets
Stable perfusion
Systolic blood pressure appropriate for age and baseline
No ongoing dysrhythmia
Glucose safety during insulin therapy
Glucose 6 to 10 mmol/L target range during treatment
Dextrose support if glucose trending down
Potassium reassessment schedule
Repeat potassium 30 to 60 minutes after temporizing therapy
Repeat potassium q 1 to 2 hours until stable trend
Key concepts
Core pathophysiology
Cardiac membrane depolarization from elevated extracellular potassium
Conduction slowing and bradyarrhythmias
Ventricular dysrhythmias and asystole risk
ECG severity may not correlate with serum potassium
Dangerous ECG changes can occur at moderate potassium levels
Severe hyperkalemia can occur with minimal ECG change
History
High-risk features and triggers
Presentation pattern
Weakness or paralysis
Ascending weakness
Periodic paralysis pattern
Palpitations or syncope
Presyncope or near syncope
Sudden collapse
Chest pain or dyspnea
Arrhythmia related symptoms
Heart failure symptoms from conduction disturbance
Renal and volume context
Chronic kidney disease
Missed dialysis session
Recent decline in urine output
Acute kidney injury risks
Dehydration or sepsis
Obstructive symptoms
Medication and exposure risks
Renin angiotensin aldosterone system blockade
ACE inhibitor
ARB
Mineralocorticoid receptor antagonist
Potassium retention drugs
Trimethoprim
NSAID
Potassium supplements and salt substitutes
Potassium chloride tablets
Salt substitute containing potassium
Cellular shift causes
Beta blocker
Digoxin toxicity risk context
Tissue breakdown risks
Rhabdomyolysis context
Prolonged immobilization
Crush injury
Tumor lysis context
Hematologic malignancy
Recent chemotherapy
Endocrine and metabolic risks
Diabetes with insulin deficiency
Missed insulin
DKA symptoms
Adrenal insufficiency
Chronic steroid use
Primary adrenal disease history
Physical Exam
Focused exam priorities
Perfusion and rhythm
Bradycardia
Junctional rhythm suspicion
Hypoperfusion signs
Hypotension
Shock physiology
Altered mental status
Neuromuscular findings
Proximal muscle weakness
Difficulty rising or lifting arms
Reduced grip strength
Flaccid paralysis
Symmetric pattern
Sensation often preserved
Volume and renal clues
Fluid overload
Peripheral edema
Pulmonary crackles
Dehydration
Dry mucous membranes
Poor skin turgor
PITFALLS
Common pitfalls
Reassuring appearance despite high risk arrhythmia potential
Minimal symptoms with dangerous ECG findings
Normal initial vital signs with impending conduction failure
Overreliance on ECG absence of changes
Severe hyperkalemia with nonspecific ECG
Rapid rise in potassium with limited early ECG signs
Differential Diagnosis
Hyperkalemia etiologies and mimics
True hyperkalemia etiologies
Reduced excretion
Acute kidney injury
ICD-10 N17.9
SNOMED CT acute kidney injury
Chronic kidney disease
ICD-10 N18.9
SNOMED CT chronic kidney disease
Hypoaldosteronism
Type 4 renal tubular acidosis
Primary adrenal insufficiency
Cellular shifts
Metabolic acidosis
Diabetic ketoacidosis
Lactic acidosis
Hyperosmolar states
Insulin deficiency
Hyperglycemia related shifts
Increased intake
Potassium supplements
Overdose
Iatrogenic IV potassium
Salt substitutes
Dietary excess with CKD
Hidden potassium load
Cell breakdown
Rhabdomyolysis
ICD-10 M62.82
SNOMED CT rhabdomyolysis
Tumor lysis syndrome
ICD-10 E88.3
SNOMED CT tumor lysis syndrome
Pseudohyperkalemia
Hemolysis in sample
Difficult venipuncture
Prolonged tourniquet
Marked leukocytosis or thrombocytosis
Serum potassium falsely elevated
Plasma potassium comparison helpful
ECG mimics and alternate causes of bradyarrhythmia
Other causes of similar ECG patterns
Sodium channel blocker toxicity
Tricyclic antidepressant overdose
Flecainide overdose
Hypocalcemia
QT prolongation prominence
Tetany signs
Acute myocardial ischemia
Conduction disturbance from ischemia
Troponin positive pattern
Laboratory Tests
Core hyperkalemia evaluation
Essential labs
Basic metabolic panel
Potassium confirmation on non-hemolyzed sample
Creatinine for excretion capacity
Glucose
Baseline before insulin
Hypoglycemia risk tracking after insulin
Venous blood gas
pH for acidosis contribution
Bicarbonate estimation support
Magnesium
Dysrhythmia cofactor
Replacement planning
Etiology labs
Creatine kinase
Rhabdomyolysis assessment
Severity tracking with renal risk
Lactate
Shock and acidosis assessment
Sepsis evaluation support
Beta hydroxybutyrate
DKA confirmation
Trend with treatment
Cortisol testing when indicated
Adrenal crisis suspicion
Consider before steroid therapy if stable
Hematology and artifacts
Pseudohyperkalemia evaluation
Repeat potassium
Plasma potassium if high platelets or WBC
Repeat draw without fist clenching
CBC
Thrombocytosis association
Leukocytosis association
Pitfalls and interpretation
Interpretation pearls
Severe hyperkalemia definition
Potassium >= 6.5 mmol/L
Any potassium with ECG changes
Rapidly rising potassium risk
Tissue breakdown causes
Acute renal failure progression
Diagnostic Tests
Scoring Systems
Risk stratification frameworks
Hyperkalemia severity categories
Mild 5.5 to 5.9 mmol/L
Moderate 6.0 to 6.4 mmol/L
Severe >= 6.5 mmol/L or ECG changes
Dialysis trigger frameworks
AEIOU indications
Acidosis refractory
Electrolytes refractory hyperkalemia
Intoxications dialyzable
Overload refractory pulmonary edema
Uremic complications
MRI
MRI for alternate diagnoses
Spinal cord pathology evaluation when focal deficits
Myelopathy suspicion
Cauda equina suspicion
MRI limitations in hyperkalemia care
Not a diagnostic test for potassium level
Do not delay temporizing therapy for imaging
CT
CT for underlying cause
CT abdomen pelvis for suspected obstruction
Hydronephrosis evaluation if unclear ultrasound
Mass or stone evaluation
CT for rhabdomyolysis complications when indicated
Compartment syndrome evaluation adjunct
Trauma related tissue injury assessment
Ultrasound
Point-of-care ultrasound applications
Volume status and cardiac function
IVC assessment for volume guidance
LV function assessment for shock context
Renal ultrasound for obstruction
Hydronephrosis detection
Bladder distension and retention
Dialysis access evaluation support
AV fistula patency clues
Catheter complication suspicion
Disposition
Level of care decisions
Admission criteria
Severe hyperkalemia
Potassium >= 6.5 mmol/L
Any ECG changes attributable to hyperkalemia
Ongoing need for temporizing therapy
Rebound potassium risk
Persistent renal failure
Dialysis requirement
Missed dialysis with hyperkalemia
Refractory hyperkalemia despite therapy
ICU criteria
Dysrhythmia or hemodynamic instability
Bradyarrhythmia requiring pacing support consideration
Ventricular dysrhythmia or arrest
Continuous infusion need
Vasopressor need
High frequency electrolyte monitoring need
Discharge considerations
Discharge eligible scenarios
Mild hyperkalemia resolved
Potassium normalized on repeat testing
No ECG changes
Clear reversible cause addressed
Medication stopped with plan
Reliable follow-up within 24 to 72 hours
Discharge not appropriate scenarios
Severe hyperkalemia at any time in ED course
Rebound risk
Arrhythmia risk
Unreliable follow-up or ongoing renal dysfunction
Rising creatinine
Oliguria
Treatment
Immediate membrane stabilization
Membrane stabilization
Calcium therapy indications
ECG changes consistent with hyperkalemia
Peaked T waves with progression concern
PR prolongation
QRS widening
Sine wave pattern
Potassium >= 6.5 mmol/L with high clinical concern
Rapid rise suspicion
Renal failure with symptoms
Calcium gluconate IV
Dose 3 g IV over 5 to 10 minutes
If no IV access delay, consider IO route
Repeat dose in 5 to 10 minutes if ECG not improving
Onset within minutes
Expected duration 30 to 60 minutes
Bridge to potassium shift and removal
Class I recommendation for life-threatening ECG changes
Based on resuscitation consensus and guideline practice
Do not delay for laboratory confirmation when ECG changes present
Calcium chloride IV
Dose 1 g IV over 5 to 10 minutes via central line preferred
Higher elemental calcium than gluconate
Tissue injury risk with extravasation
Cardiac arrest or profound instability consideration
Faster delivery in resuscitation setting
Repeat dosing guided by ECG response
Rapid intracellular shift therapies
Potassium shift therapies
Regular insulin IV with dextrose
Insulin 10 units IV
Onset 10 to 20 minutes
Peak effect 30 to 60 minutes
Dextrose strategy
If glucose < 7 mmol/L, dextrose 25 g IV
If glucose 7 to 14 mmol/L, dextrose 12.5 to 25 g IV based on trend
If glucose > 14 mmol/L, dextrose may be deferred with close monitoring
Hypoglycemia prevention
Glucose checks q 30 minutes for 2 hours
Dextrose infusion consideration if recurrent low glucose
Class I recommendation for severe hyperkalemia temporizing therapy
Used with calcium when ECG changes present
Used with removal strategy for definitive control
Nebulized albuterol
Dose 10 to 20 mg nebulized over 10 minutes
Lower doses less effective for potassium shift
Additive effect with insulin
Tachycardia and tremor monitoring
Avoid sole therapy in unstable cardiac disease
Reduced response in beta blocker use possible
Class IIa recommendation as adjunct therapy
Adjunct to insulin rather than replacement in severe cases
Helpful when hypoglycemia risk limits insulin strategy
Sodium bicarbonate IV
Dose 50 mmol IV over 5 minutes for severe metabolic acidosis
Greater effect when significant acidosis present
Limited effect in absence of acidosis
Class IIb recommendation in selected patients
Consider when pH low and hemodynamically unstable
Avoid volume overload in renal failure unless dialysis planned
Potassium removal strategies
Potassium removal
Loop diuretic if urine output present
Furosemide 20 to 80 mg IV
Higher doses in CKD may be required
Pair with isotonic crystalloid if hypovolemic
Monitor response
Urine output trend
Potassium trend
Gastrointestinal binders
Sodium zirconium cyclosilicate oral
Dose 10 g oral
Repeat dosing based on institutional protocol
Patiromer oral
Dose 8.4 to 25.2 g oral
Separation from other oral meds required
Sodium polystyrene sulfonate
Limited ED role
Bowel necrosis risk in ileus or post op states
Slower onset than shift therapies
Not a substitute for calcium and insulin in severe cases
Adjunct for rebound prevention when appropriate
Hemodialysis
Indications
Refractory hyperkalemia
Severe renal failure with ongoing rise
Life-threatening ECG changes with limited response
Coordination steps
Nephrology consult early
Vascular access planning
Class I recommendation for definitive therapy when indicated
Temporizing therapies used while arranging dialysis
Rebound risk addressed with definitive removal
Stop sources and treat the cause
Source control and cause correction
Medication holds
ACE inhibitor hold
Restart plan after follow-up
Renal function reassessment plan
ARB hold
Restart plan after follow-up
Potassium recheck plan
Spironolactone or eplerenone hold
Heart failure team follow-up if applicable
Potassium monitoring plan
Trimethoprim hold
Alternate antibiotic plan
Renal dosing adjustment review
DKA management when present
Standard DKA protocol with cautious potassium monitoring
Potassium can fall rapidly with insulin infusion
Frequent electrolyte checks required
If potassium very high, initial calcium and bolus insulin strategy may precede infusion
Arrhythmia prevention priority
Transition to protocol once stabilized
Rhabdomyolysis management when present
Aggressive isotonic fluids if not volume overloaded
Renal protection strategy
Potassium removal support via diuresis when possible
Compartment syndrome evaluation when indicated
Surgical consult triggers
Pain out of proportion consideration
Special Populations
Pregnancy
Pregnancy considerations
Maternal stabilization priority
Standard hyperkalemia temporizing therapy applicable
Continuous fetal monitoring when viable gestation and resources available
Medication considerations
Calcium gluconate compatible with pregnancy care
Insulin and dextrose compatible with pregnancy care
Obstetric consultation triggers
Maternal instability
Fetal distress on monitoring
Geriatric
Geriatric considerations
Higher medication burden risk
Polypharmacy review focus on RAAS blockade
NSAID use common contributor
Higher hypoglycemia risk with insulin therapy
Lower glycogen reserve
More frequent glucose checks
Lower physiologic reserve for dysrhythmia tolerance
Lower threshold for ICU
Lower threshold for dialysis planning
Pediatrics
Pediatric considerations
Weight-based dosing
Calcium gluconate 60 mg/kg IV up to 3 g
Regular insulin 0.1 units/kg IV up to 10 units
Dextrose dosing
Dextrose 0.25 g/kg IV
Concentration selection to reduce phlebitis risk
Common pediatric causes
Congenital adrenal hyperplasia
Acute renal failure from dehydration
Background
Epidemiology
Epidemiology and burden
ICD-10 hyperkalemia
ICD-10 E87.5
SNOMED CT hyperkalemia
High-risk settings
Chronic kidney disease and dialysis population
RAAS inhibitor use with reduced renal reserve
Common precipitating scenarios
Missed dialysis
Acute kidney injury from infection or dehydration
Pathophysiology
Mechanisms
Reduced renal excretion
Decreased distal sodium delivery
Reduced aldosterone effect
Transcellular shift
Acidemia contribution
Insulin deficiency contribution
Increased release from cells
Tissue necrosis
Hemolysis and rhabdomyolysis
Therapeutic Considerations
Treatment principles
Membrane stabilization first when ECG changes
Calcium effect on threshold potential
Rapid onset and short duration
Shift therapies buy time
Insulin increases cellular uptake of potassium
Beta agonists increase Na K ATPase activity
Removal is definitive
Dialysis most effective when renal failure present
Diuresis effective only with adequate urine output
Rebound prevention
Ongoing potassium source control
Repeat potassium checks after temporizing therapy wears off
Patient Discharge Instructions
Copy discharge instructions
Discharge instructions set
Condition summary
Elevated potassium improved on repeat testing
Cause addressed or suspected and plan provided
Medication instructions
Hold listed potassium raising medications until clinician review
Avoid salt substitutes containing potassium
Diet guidance
Avoid high potassium foods until follow-up labs
Hydration guidance if appropriate for kidney and heart status
Follow-up plan
Potassium and creatinine recheck within 24 to 72 hours
Primary care or nephrology follow-up arranged
Return to ED now criteria
Weakness worsening
Palpitations or fainting
Chest pain or shortness of breath
New confusion or severe fatigue
References
Clinical guidelines and evidence sources
Evidence sources
American Heart Association ACLS guidance for hyperkalemia management and resuscitation recommendations
Class I recommendations for calcium in life-threatening hyperkalemia with ECG changes
Class I recommendations for insulin based potassium shift therapy in severe hyperkalemia
Kidney Disease Improving Global Outcomes guidance for acute kidney injury and emergent dialysis indications
Refractory hyperkalemia as emergent renal replacement therapy indication
Integration with volume status and acid base status
Expert consensus emergency medicine practice for immediate treatment when ECG changes present
Do not delay temporizing therapy while repeating potassium to exclude hemolysis
Repeat potassium monitoring after temporizing therapy to detect rebound
Source file reference
Formatting and hierarchy constraints followed for database optimized checklist output
Units preference using mmol/L and blood gas mmHg
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.